Department of Rheumatology, Alicante General University Hospital, Institute of Sanitary and Biomedical Research (ISABIAL), Alicante, Spain.
Department of Clinical Medicine, Miguel Hernández University, Elche, Spain.
PLoS One. 2021 Mar 23;16(3):e0248869. doi: 10.1371/journal.pone.0248869. eCollection 2021.
This study analyzed the impact of a categorized approach, based on patients' prognosis, on major outcomes and explanators in patients hospitalized for COVID-19 pneumonia in an academic center in Spain.
Retrospective cohort study (March 3 to May 2, 2020). Patients were categorized according to the followed clinical management, as maximum care or limited therapeutic effort (LTE). Main outcomes were all-cause mortality and need for invasive mechanical ventilation (IMV). Baseline factors associated with outcomes were analyzed by multiple logistic regression, estimating odds ratios (OR; 95%CI).
Thirty-hundred and six patients were hospitalized, median age 65.0 years, 57.8% males, 53.3% Charlson index ≥3. The overall all-cause fatality rate was 15.0% (n = 46). Maximum care was provided in 238 (77.8%), IMV was used in 38 patients (16.0%), and 5.5% died. LTE was decided in 68 patients (22.2%), none received IMV and fatality was 48.5%. Independent risk factors of mortality under maximum care were lymphocytes <790/mm3, troponin T >15ng/L and hypotension. Advanced age, lymphocytes <790/mm3 and BNP >240pg/mL independently associated with IMV requirement.
Overall fatality in the cohort was 15% but markedly varied regarding the decided approach (maximum care versus LTE), translating into nine-fold higher mortality and different risk factors.
本研究分析了一种基于患者预后的分类方法对西班牙一家学术中心因 COVID-19 肺炎住院患者主要结局和解释因素的影响。
回顾性队列研究(2020 年 3 月 3 日至 5 月 2 日)。根据所遵循的临床管理,患者分为最大治疗组或有限治疗组(LTE)。主要结局为全因死亡率和需要有创机械通气(IMV)。通过多因素逻辑回归分析与结局相关的基线因素,估计比值比(OR;95%CI)。
306 例患者住院,中位年龄 65.0 岁,57.8%为男性,53.3%Charlson 指数≥3。总体全因死亡率为 15.0%(n=46)。238 例(77.8%)接受最大治疗,38 例(16.0%)使用 IMV,5.5%死亡。68 例(22.2%)决定 LTE,无一例接受 IMV,死亡率为 48.5%。最大治疗下死亡的独立危险因素是淋巴细胞<790/mm3、肌钙蛋白 T>15ng/L 和低血压。高龄、淋巴细胞<790/mm3 和 BNP>240pg/mL 是与需要 IMV 独立相关的因素。
该队列的总体死亡率为 15%,但根据所决定的治疗方法(最大治疗与 LTE)差异很大,死亡率相差 9 倍,且风险因素也不同。